ZBD(SH:603567) Hua Xia Shi Bao·2025-05-09 03:52Core Viewpoint - The traditional Chinese medicine industry in China is rapidly developing, supported by national policies, with Zhenbaodao (603567.SH) emerging as a leading enterprise in the field, demonstrating stable performance and growth in its financial metrics [1][2][9]. Financial Performance - In 2024, Zhenbaodao achieved an operating income of 2.704 billion yuan and a net profit of 438 million yuan, with the core pharmaceutical industrial revenue reaching 2.376 billion yuan, reflecting a year-on-year growth of 20.23% [1][2][3]. - As of the end of 2024, the company's total assets amounted to 12.713 billion yuan, an increase of 1.98% from the beginning of the year, while the net assets reached 7.801 billion yuan, growing by 3.34% [2][3]. Industry Context - The pharmaceutical manufacturing sector is showing strong resilience amid structural adjustments, with a reported increase of 3.4% in the added value of large-scale pharmaceutical industries in 2024 [2]. - The overall revenue for large-scale pharmaceutical enterprises reached 29.7627 billion yuan, with profits totaling 4.0509 billion yuan, indicating a profit growth rate that outpaces the national industrial average by 2.4 percentage points [2]. Business Operations - Zhenbaodao's pharmaceutical industrial segment is its core business, contributing nearly 90% to its total revenue, with robust manufacturing capabilities across multiple production bases [3]. - The company has established a diverse product portfolio, including raw materials, chemical preparations, traditional Chinese medicine preparations, and biological preparations, supported by ongoing research and development [3]. Innovation and Development - Zhenbaodao is actively fostering new productive forces in the pharmaceutical industry through technological breakthroughs and innovative resource allocation, focusing on the development of innovative and generic drugs [4][5]. - The company has established partnerships with renowned universities and research institutions to enhance the quality standards of traditional Chinese medicine injections and other significant clinical research projects [4]. Social Responsibility and Industry Impact - Zhenbaodao emphasizes its social responsibility as a core strategy, contributing to public health and societal value creation, particularly in the context of increasing chronic disease treatment demands [7][8]. - The company has engaged in various social welfare initiatives, supporting education, culture, and health, thereby enhancing its brand value and long-term growth potential [8]. Recognition and Future Outlook - Zhenbaodao has received numerous accolades, including being listed among the top 100 pharmaceutical companies in China and recognized for its contributions to social responsibility and digital transformation [8][9]. - The ongoing policy support for traditional Chinese medicine is expected to further drive market growth, with Zhenbaodao positioned to leverage these opportunities through innovation and social responsibility [9].